88 results on '"Fuchs C.S."'
Search Results
2. Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
3. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies
4. Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies
5. Nut consumption and risk of colorectal cancer in women
6. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
7. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
8. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
9. Mendelian randomization analysis of n-6 polyunsaturated fatty acid levels and pancreatic cancer risk.
10. Smoking modifies pancreatic cancer risk loci on 2q21.3.
11. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies.
12. Genome-wide association study data reveal genetic susceptibility to chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma risk.
13. Body mass index and Barrett's oesophagus in women
14. Sugar-sweetened beverage and sugar intake during adolescence and risk of colorectal cancer precursors: a large prospective U.S. cohort study
15. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies
16. 197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
17. 1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
18. 1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials
19. KEYNOTE-585 : Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer
20. Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
21. Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)
22. Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062
23. Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutation
24. Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
25. Socioeconomic discrepancies in survival of stage IV colorectal cancer
26. Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer
27. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
28. Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome
29. Habitual intake of flavonoid subclasses and risk of colorectal cancer in 2 large prospective cohorts
30. KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
31. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
32. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility
33. 125O - Pembrolizumab + chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
34. LBA44 - Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062
35. 791P - Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)
36. Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women
37. 231TiP KEYNOTE-059: Phase 2 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma
38. 232TiP KEYNOTE-061: Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
39. 784TiP - Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer
40. 616PD - Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer
41. 572P - Socioeconomic discrepancies in survival of stage IV colorectal cancer
42. 529P - Survival of stage IV colorectal cancer: Interaction of cancer location, microsatellite instability and KRAS mutation
43. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
44. LBA28_PR - KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
45. 1592P - Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
46. A prospective study on oral contraceptive use and colorectal cancer
47. Dietary carotenoids and risk of colorectal cancer in a pooled analysis of 11 cohort studies
48. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies
49. Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
50. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.